ReviewJournal of cancer research and clinical oncology2026
Malignant uterine PEComa: a narrative literature review and challenging case report.
Review in Journal of cancer research and clinical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Uterine perivascular epithelioid cell tumors (PEComas) are exceptional mesenchymal neoplasms of the gynecologic tract that often mimic common uterine lesions and lack pathognomonic clinical or radiologic features. We report a malignant uterine PEComa in a 44-year-old woman presenting with abnormal uterine bleeding and pelvic pain. Preoperative imaging suggested a fibroid, but definitive diagnosis followed hysterectomy: in fact, histopathology showed epithelioid cells arranged around a rich vasculature with high-grade cytologic atypia, brisk mitotic activity, and necrosis, all features consistent with malignant behavior. Subsequent immunophenotyping demonstrated co-expression of melanocytic and smooth-muscle markers. The disease was organ-confined; no adjuvant therapy was administered, and the patient remains disease-free at 24 months under structured surveillance. To contextualize this case, we conducted a narrative review of the literature through October 2025, synthesizing epidemiology, pathogenesis, diagnosis, histology, treatment, and outcomes of uterine PEComas. Evidence supports complete surgical excision as the cornerstone of management for localized disease. For advanced or recurrent tumors, inhibitors of the mammalian target of rapamycin (mTOR) represent a rational option given frequent dysregulation of this pathway. Overall, malignant uterine PEComa requires multidisciplinary evaluation, pathology-driven diagnosis, and long-term follow-up; accumulating case-based evidence is refining risk stratification and informing the selective use of targeted therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.